Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd Share Price Today: Live Updates & Key Insights

Get insights on Tatva Chintan Pharma Chem Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Tatva Chintan Pharma Chem Ltd Share Price Chart

Tatva Chintan Pharma Chem Ltd Fundamentals

Traded Volume: 2,16,017

Market Cap(Cr): 3,509

Avg Traded Price 1625.93

1 Year return 73.14%

Upper Circuit 1,506.7

Lower Circuit 1,428.5

P/E TTM 198.00

P/B Ratio 8.00

Traded Value(Cr) 3240.69

EPS TTM 7.582

Book value 7.582

Dividend 0.00%

Tatva Chintan Pharma Chem Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Tatva Chintan Pharma Chem Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Tatva Chintan Pharma Chem Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W +10.33%

1M +43.61%

3M +39.66%

1Y +73.14%

YTD +69.02%

Tatva Chintan Pharma Chem Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Tatva Chintan Pharma Chem Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 2.03L

Day Before Yesterday 18.14L

1W Avg 7.67L

1M Avg 4.29L

3M Avg 1.93L

Tatva Chintan Pharma Chem Ltd Technical Details

Tatva Chintan Pharma Chem Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 1450

Support 2 1400

Support 3 1372

Pivot Point : 1478

Resistance 1 1528

Resistance 2 1557

Resistance 3 1607

Tatva Chintan Pharma Chem Ltd Corporate Actions

Tatva Chintan Pharma Chem Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Tatva Chintan Pharma Chem Ltd’s capital allocation strategies.

All

Ex-Date 12-Sep-2025 Type D Description 1.00/share@10.00% Record Date 12-Sep-2025 Ratio 10.00

Ex-Date 06-Sep-2024 Type D Description 2.00/share@20.00% Record Date 07-Nov-2025 Ratio 20.00

Ex-Date 08-Sep-2023 Type D Description 2.00/share@20.00% Record Date 08-Sep-2023 Ratio 20.00

Ex-Date 08-Sep-2022 Type D Description 2.00/share@20.00% Record Date 09-Sep-2022 Ratio 20.00

Dividends

Announcement Date 12-Sep-2025 Ex Dividend Date 12-Sep-2025 Dividend(%) 10

Announcement Date 06-Sep-2024 Ex Dividend Date 06-Sep-2024 Dividend(%) 20

Announcement Date 08-Sep-2023 Ex Dividend Date 08-Sep-2023 Dividend(%) 20

Announcement Date 08-Sep-2022 Ex Dividend Date 08-Sep-2022 Dividend(%) 20

Bonus

No Bonus has been declared by TATVA

Splits

No Split has been declared by TATVA

Others

Rights No Rights has been declared by TATVA

Tatva Chintan Pharma Chem Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Tatva Chintan Pharma Chem Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Tatva Chintan Pharma Chem Ltd's relative performance and valuation against major competitors.

Stock Name Styrenix Performance Materials Ltd ₹2352.10 (+1.15%) M. Cap (Cr) 41.37 1 Yr Return (%) -7.90% P/E (TTM) 18.31 PB Ratio 3.54

Stock Name Neogen Chemicals Ltd ₹1452.30 (-0.21%) M. Cap (Cr) 38.31 1 Yr Return (%) -36.82% P/E (TTM) 113.89 PB Ratio 4.85

Stock Name Camlin Fine Sciences Ltd ₹196.01 (+3.54%) M. Cap (Cr) 36.85 1 Yr Return (%) +75.32% P/E (TTM) -32.03 PB Ratio 4.03

Stock Name Tatva Chintan Pharma Chem Ltd ₹1500.20 (+3.28%) M. Cap (Cr) 35.09 1 Yr Return (%) +73.14% P/E (TTM) 197.86 PB Ratio 4.76

Stock Name Rossari Biotech Ltd ₹627.60 (-1.93%) M. Cap (Cr) 34.76 1 Yr Return (%) -22.65% P/E (TTM) 25.44 PB Ratio 2.93

Stock Name Vishnu Chemicals Ltd ₹494.90 (-1.51%) M. Cap (Cr) 33.31 1 Yr Return (%) -10.47% P/E (TTM) 24.06 PB Ratio 3.59

Stock Name Fineotex Chemical Ltd ₹26.36 (+3.58%) M. Cap (Cr) 30.20 1 Yr Return (%) -30.47% P/E (TTM) 28.97 PB Ratio 4.13

Tatva Chintan Pharma Chem Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Tatva Chintan Pharma Chem Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 23.90 Mar 2024 102.78 Mar 2023 23.73 Mar 2022 19.89 Mar 2021 22.75

PARTICULARS Investing Activities Mar 2025 -65.25 Mar 2024 -120.54 Mar 2023 -101.12 Mar 2022 -196.81 Mar 2021 -20.40

PARTICULARS Financing Activities Mar 2025 16.57 Mar 2024 30.54 Mar 2023 37.82 Mar 2022 234.96 Mar 2021 -8.58

PARTICULARS Net Cash Flow Mar 2025 -24.78 Mar 2024 12.80 Mar 2023 -39.59 Mar 2022 58.05 Mar 2021 -6.23

Tatva Chintan Pharma Chem Ltd Shareholding Pattern

This shows the ownership breakdown of Tatva Chintan Pharma Chem Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 72.02%

Public 20.72%

Other Institutions 0.05%

FII 3.4%

Mutual Funds 3.82%

About Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Limited was formerly incorporated as 'Tatva Chintan Pharma Chem Private Limited' on 12 June 1996. The status of the Company converted from Private Limited into a Public Limited Company from 27 January 2021 and the name of Company changed from 'Tatva Chintan Pharma Chem Private Limited' to 'Tatva Chintan Pharma Chem Limited'. The Company is promoted by Mr. Chintan Nitin Kumar Shah, Mr. Ajay Kumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani. The Company is a globally recognized specialty chemical player with several market leading products in its portfolio. The Company is primarily engaged in manufacturing, distribution and selling of specialty chemicals i.e., Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA), Electrolyte Salts and Solutions (ESS), Pharmaceutical and Agrochemical Intermediates and Other Specialty Chemicals (PASC). These products cater to diverse industries such as pharmaceuticals, agrochemicals, automotive, electronics, resins and polymers, flavours and fragrances, personal care and disinfectants, oil field and energy storage.The Company operate through two world class manufacturing facilities located at Dahej and Ankleshwar in Gujarat both of which are strategically located very close to the Hazira Port. These units provide the Company cost and logistics advantage and enabling seamless export and import operations. The Company's manufacturing facilities obtained ISO 9001:2015 and 14001:2015 certification for robust quality management systems. Employing modern equipment like reactors, assembly lines, ANFDs, centrifuges and RCVDs, enabled the Company to undertake multiple chemistry process. The Company successfully established an integrated model comprising world class manufacturing infrastructure, complex & chemical processes, warehousing facilities and technically sound R&D capabilities, which enables to achieve high operational efficiency and quality, to innovate & customize and to ensure sustainable operations with wide offerings. The Company has sophisticated quality control lab equipped with modern analytical equipment, enabling it to detect impurities upto PPM levels and achieve `ultra-pure'grade certification. The Company Promoters identified an opportunity in manufacturing Phase Transfer Catalyst (PTC), which is a niche segment within the specialty chemicals space. With PTC as the base, the Company have marked presence in the entire value chain including PTC, Structure Directing Agents (SDA), Electrolyte Salts (ES) and Pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC).The Company have a dedicated Department of Scientific and Industrial Research (DSIR) approved R&D centre at its Vadodara facility where qualified and experienced in-house R&D team focus on development of new products and improvement in current manufacturing processes. The Company is having modern systems and analytical development laboratory with state-of-the-art instrumentation.In 2004, the Company received licence from the FDA, Gujarat at its Ankleshwar manufacturing plant.In 2007, the Company commenced Ankleshwar manufacturing facility and increased the expansion of manufacturing capacity.In 2011, the Company started commercial manufacturing of Structure Directing Agents (SDA).In 2015, the Company was accredited Appreciation Certificate for the Ankleshwar Plant from the Office of the Chief Commission of Central Excise, Customs & Service Tax, Vadodara Zone for its contribution to revenue and voluntary compliance with tax laws. The Company achieved revenue of nearly Rs 1 bn. The Company established a warehousing plant in The Netherlands. Tatva Chintan USA Inc. was incorporated as a wholly owned Subsidiary of TCPCL.In 2016, the Company was accorded the status of a two-star export house for the Ankleshwar plant from the Directorate General of Foreign Trade (DGFT), Ministry of Commerce and Industry (MoCI), Government of India (GoI).In 2017, manufacturing plant was established in Dahej, Gujarat. In 2018, the R&D facility was set up in Vadodara.Tatva Chintan Europe BV, was incorporated as wholly owned Subsidiary of the Company in year 2019.In FY 2019-20, the Company's Ankleshwar unit was converted to a zero liquid effluent discharge facility. The products proved efficiency to ensure lower by-products and waste generation in chemical processes.Additionally, the Company participated in the ` Together for Sustainability' initiatives whereby sustainability sourcing practices of chemical suppliers, like ecological and social aspects were assessed. Under this initiative, the Company involved Ecovadis to audit sustainability practices and performance, the results of which were above the industry average. This created a robust initiative and focused on retaining key customers who consider sustainability an important parameter to do business. In 2020, the Company achieved another Rs 2 billion revenue.In 2021, the manufacturing capacity at Dahej facility in Gujarat increased giving rise to aggregate installed reactor manufacturing capacity of the Company from 160 KL and 10 Assembly Lines to 280 KL and 17 Assembly Lines respectively.The Company launched its Initial Public Offer cum Offer for Sale of 46,16,804 Equity Shares by raising funds from public aggregating to Rs 500 Crore, comprising a Fresh Issue of 20,77,562 Equity Shares aggregating to Rs 225 Crore and an Offer for Sale of 25,39,242 Equity Shares aggregating to Rs 275 Crore in July, 2021. The Company commenced commercial production from the newly expanded facility at Dahej SEZ. With this, the installed reactor capacity increased to 500 KL from 294 KL and assembly lines increased from 27 to 39 in 2023-24. It started production at Distillation Plant in FY 2025.

Chairman / Executive Director / M D / Promoter

Chintan Nitinkumar Shah

Registered office No 502/17 GIDC Estate, Ankleshwar, Bharuch, Gujarat, 393002

FAX :+91-75730-46951/46952

Background

Incorporation Year 1996

Face Value ₹10.00

Market Lot 1

Tatva Chintan Pharma Chem Ltd Latest News

VIEW MORE NEWS

FAQs on Tatva Chintan Pharma Chem Ltd